Linda E Kelemen

No ORCID on file · 11 papers in corpus · active 2014-2023

Study types

  • other 5
  • article 3
  • preprint 3

Condition tags

  • endometriosis 10
  • mesh:D004715 2
preprint 2023
·doi:10.1158/1055-9965.c.6515916

AbstractBackground: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian canc…

preprint 2023
·doi:10.1158/1055-9965.c.6515916.v1

AbstractBackground: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian canc…

preprint 2021
·doi:10.1101/2021.09.16.21262993

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumor suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory repo…

article 2021
The Journal of Pathology ·doi:10.1002/path.5849

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory rep…

other 2018
The journal of pathology. Clinical research ·doi:10.1002/cjp2.109

We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemi…

other 2017
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology ·doi:10.1158/1055-9965.EPI-17-0367

Background: Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patie…

other 2017
Cancer causes & control : CCC ·doi:10.1007/s10552-016-0841-3

PURPOSE: Cancer antigen 125 (CA125) is a glycoprotein expressed by epithelial cells of several normal tissue types and overexpressed by several epithelial cancers. Serum CA125 levels are mostly used as an aid in the diagnosis of ovarian can…

article 2017
Cancer causes & control : CCC ·doi:10.1007/s10552-017-0855-5
other 2015
Journal of genetics and genome research ·doi:10.23937/2378-3648/1410017

Disruption in circadian gene expression, whether due to genetic variation or environmental factors (e.g., light at night, shiftwork), is associated with increased incidence of breast, prostate, gastrointestinal and hematologic cancers and g…

article 2015
Fertility and sterility ·doi:10.1016/j.fertnstert.2015.09.023
other 2014
Cancer research ·doi:10.1158/0008-5472.CAN-13-1051

A missense single-nucleotide polymorphism (SNP) in the immune modulatory gene IL1A has been associated with ovarian cancer risk (rs17561). Although the exact mechanism through which this SNP alters risk of ovarian cancer is not clearly unde…